REMINDER: Our focusIR Investor Webinar takes place TONIGHT with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRtw Biotech Regulatory News (RTW)

Share Price Information for Rtw Biotech (RTW)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.36
Bid: 1.36
Ask: 1.38
Change: -0.02 (-1.45%)
Spread: 0.02 (1.471%)
Open: 1.36
High: 1.36
Low: 1.36
Prev. Close: 1.38
RTW Live PriceLast checked at -
RTW Venture is an Investment Trust

To achieve positive absolute performance and superior long-term capital appreciation, with a focus on forming, building, and supporting world-class life sciences, biopharmaceutical and medical technology companies.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Edison issues flash on RTW Biotech Opportunities (RTWBIO): Significant acquisition of Arix Bioscience’s assets

1 Nov 2023 10:51

Edison Investment Research Limited Edison issues flash on RTW Biotech Opportunities (RTWBIO): Significant acquisition of Arix Bioscience’s assets 01-Nov-2023 / 10:51 GMT/BST The issuer is solely responsible for the content of this announcement.


 

London, UK, 1 November 2023

 

Edison issues flash on RTW Biotech Opportunities (RTWBIO): Significant acquisition of Arix Bioscience’s assets

On 1 November 2023, RTW Biotech Opportunities (RTWBIO), a full life cycle biotech investor, announced what it considers to be a transformational deal. It plans to acquire the assets of UK-listed Arix Bioscience in an all-share transaction, which on a pro-forma basis would increase RTWBIO’s NAV by c $550m (c 63%). The deal brings the prospects of increased liquidity in RTWBIO’s shares and a more efficient cost base, and potential for a higher RTWBIO valuation. Arix’s shareholders would receive new RTWBIO shares at an implied c 46% premium to the level before Arix announced a strategic review. Meanwhile, RTWBIO’s management team anticipates that the deal would be single-digit accretive to the company’s NAV per share at completion.

During 2022 and so far in 2023, RTWBIO has made nine new investments and had seven successful IPOs or exits of portfolio companies. The acquisition would bring c $128m of Arix’s liquid assets, of which c $60m is expected to be in cash following completion of the scheme and the cost of the deal. RTWBIO intends to invest this capital in both public and private assets and can deploy cash quickly via investment in its ‘other public’ portfolio, which is made up of listed companies held by other RTW funds, to minimise cash drag. It can also deploy capital through its royalty and structured finance strategy, which provides an income stream with returns that are uncorrelated with equity returns and stock market volatility.Click here to view the full report.All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached – across institutions, family offices, wealth managers and retail investors – Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first company in-market 17 years ago, Edison has more than 100 employees and covers every economic sector. Headquartered in London, Edison also has offices in New York, Sydney and Wellington.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Mel Jenner +44 (0)20 3077 5700 investmenttrusts@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on:

LinkedIn www.linkedin.com/company/edison-group-/

Twitter  www.twitter.com/Edison_Inv_Res

YouTube www.youtube.com/edisonitv


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1762757 01-Nov-2023 

corporate announcement transmitted by EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
31st Mar 20237:00 amRNSAnnual Financial Report
30th Mar 20234:35 pmRNSPrice Monitoring Extension
29th Mar 202310:47 amRNSPortfolio Company Update: Strategic Financing
16th Mar 20234:00 pmRNSDirector Declaration
14th Mar 20237:00 amRNSMonthly Valuation Update
13th Mar 20233:20 pmRNSUpdate re Silicon Valley Bank exposure
1st Mar 20232:45 pmRNSNew Investment in Cargo Therapeutics
1st Mar 202310:00 amRNSNew Investment in Oricell Therapeutics
14th Feb 20237:00 amRNSMonthly Valuation Update
13th Feb 20234:51 pmRNSPortfolio Company Update
26th Jan 202311:32 amRNSQuotedData's Weekly News & Interview
25th Jan 20237:00 amRNSQuarterly Update
20th Jan 20234:29 pmRNSUpdate research from QuotedData
16th Jan 20237:00 amRNSNet Asset Value(s)
22nd Dec 20224:23 pmRNSDirector/PDMR Shareholding
19th Dec 202211:17 amRNSResult of General Meeting
14th Dec 20227:00 amRNSNet Asset Value(s)
13th Dec 202210:01 amRNSEdison issues flash on RTW Venture Fund (RTW)
8th Dec 20225:57 pmRNSMaterial Update from Portfolio Company
7th Dec 20221:00 pmRNSNew Investment in Apogee Therapeutics
1st Dec 20227:00 amRNSPublication of Circular & Convening of EGM
30th Nov 20222:00 pmRNSDirector/PDMR Shareholding
28th Nov 20227:00 amRNSChange of status for US federal tax - PTP to PFIC
14th Nov 20227:00 amRNSNet Asset Value(s)
4th Nov 20224:04 pmRNSDirector/PDMR Shareholding
1st Nov 20225:07 pmRNSDirector/PDMR Shareholding
25th Oct 20227:00 amRNSQuarterly Update
20th Oct 20227:00 amRNSEdison issues review on RTW Venture Fund (RTW)
14th Oct 20227:00 amRNSNet Asset Value(s)
22nd Sep 20227:00 amRNSDirector/PDMR Shareholding
16th Sep 20227:00 amRNSPortfolio Company Update: Third Harmonic Bio IPO
15th Sep 20227:30 amRNSNet Asset Value(s)
15th Sep 20227:00 amRNSHalf-year Report
17th Aug 202212:00 pmRNSNotice of Interim Report
12th Aug 20227:00 amRNSNet Asset Value(s)
26th Jul 20227:00 amRNSQuarterly Update
19th Jul 20227:55 amRNSAdditional Investment in Portfolio Company
15th Jul 20227:00 amRNSNet Asset Value(s)
6th Jul 20227:00 amRNSPortfolio Company Transaction Update
21st Jun 20225:33 pmRNSResult of AGM
13th Jun 20227:00 amRNSNet Asset Value(s)
17th May 20227:00 amRNSNotice of AGM
13th May 20227:00 amRNSNet Asset Value(s)
28th Apr 20227:00 amRNSQuarterly Update
14th Apr 20227:05 amRNSNew Investment
14th Apr 20227:00 amRNSNet Asset Value(s)
4th Apr 20224:23 pmRNSDirector/PDMR Shareholding
4th Apr 20224:22 pmRNSDirector/PDMR Shareholding
31st Mar 20227:00 amRNSAnnual Financial Report
14th Mar 20227:00 amRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.